- Report
- October 2024
- 181 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 384 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Clinical Trials
- June 2024
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- March 2024
- 120 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- April 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- March 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- October 2023
- 71 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- November 2021
- 620 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- October 2024
- 2609 Pages
Global
From €2416EUR$2,655USD£2,071GBP

Valganciclovir is an antiviral drug used to treat infections caused by certain viruses, such as cytomegalovirus (CMV). It is used in the treatment of infectious diseases, including CMV retinitis, a viral infection of the retina that can cause blindness. Valganciclovir is also used to prevent CMV infection in people who have received organ transplants. It works by blocking the action of the virus in the body, preventing it from multiplying and spreading.
Valganciclovir is available in tablet and oral solution form. It is usually taken twice daily, with or without food. Common side effects include nausea, vomiting, diarrhea, and headache. More serious side effects may include kidney problems, anemia, and low white blood cell count.
Valganciclovir is marketed by several pharmaceutical companies, including Genentech, Merck, and Novartis. It is also available as a generic drug. Show Less Read more